Georgene E. Hergenroeder
Pediatric Pulmonology
3500 Civic Center Blvd
Philadelphia, PA 19104
Philadelphia, PA 19104
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Pulmonary Outcomes in People with Cystic Fibrosis who Stop Chronic Daily Therapies: The HERO-2 Study.
Journal: Annals of the American Thoracic Society
Published: January 21, 2026
Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) in People with Cystic Fibrosis in the United States.
Journal: Annals of the American Thoracic Society
Published: May 16, 2025
Baseline Characteristics and Self-Reported Use of Chronic Daily Therapies of the Home Reported Outcomes With CFTR Modulator Therapy (HERO-2) Cohort.
Journal: Pediatric pulmonology
Published: January 16, 2025
Using Real-World Research to Study the Impact of Chronic Daily Therapy Discontinuation in Cystic Fibrosis: The Home-Reported Outcomes in Cystic Fibrosis 2 Study Design.
Journal: CHEST pulmonary
Published: June 29, 2024
Factors associated with prescription of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: June 10, 2024
The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: May 09, 2023
Seroprevalence and clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis.
Journal: Pediatric pulmonology
Published: March 16, 2023
Exasperation with the lack of pulmonary exacerbation treatment standardization.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: August 23, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026